Literature DB >> 18633450

Surface expression of Bcl-2 in chronic lymphocytic leukemia and other B-cell leukemias and lymphomas without a breakpoint t(14;18).

Brian A McCarthy1, Erin Boyle, Xue Ping Wang, Dorothy Guzowski, Santanu Paul, Rosa Catera, Joshua Trott, Xiao-jie Yan, Carlo M Croce, Rajendra Damle, Sophia Yancopoulos, Bradley T Messmer, Martin Lesser, Steven L Allen, Kanti R Rai, Nicholas Chiorazzi.   

Abstract

Since its discovery in follicular lymphoma cells at the breakpoint t(14;18), Bcl-2 has been studied extensively in many basic and clinical science settings. Bcl-2 can locate as an integral mitochondrial membrane component, where its primary role is to block apoptosis by maintaining membrane integrity. Here we show that Bcl-2 also can position on the outer cell surface membrane of B cells from patients with chronic lymphocytic leukemia (B-CLL) and certain other leukemias that do not classically possess the chromosomal breakpoint t(14;18). Although low levels of Bcl-2 can be detected on the surface membrane of apparently healthy leukemic and normal B cells, expression of Bcl-2 correlates best with spontaneous or induced apoptosis. Notably, upon induction of apoptosis, B-CLL cells were much more efficient in upregulating surface Bcl-2 than normal B cells. It is not clear if this surface membrane expression is a passive consequence of the apoptotic process or an active attempt by the B cell to abort cell death by stabilizing the plasma membrane.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18633450      PMCID: PMC2464573          DOI: 10.2119/2008.00061.McCarthy

Source DB:  PubMed          Journal:  Mol Med        ISSN: 1076-1551            Impact factor:   6.354


  39 in total

1.  MEC1 and MEC2: two new cell lines derived from B-chronic lymphocytic leukaemia in prolymphocytoid transformation.

Authors:  A Stacchini; M Aragno; A Vallario; A Alfarano; P Circosta; D Gottardi; A Faldella; G Rege-Cambrin; U Thunberg; K Nilsson; F Caligaris-Cappio
Journal:  Leuk Res       Date:  1999-02       Impact factor: 3.156

Review 2.  Cell death: critical control points.

Authors:  Nika N Danial; Stanley J Korsmeyer
Journal:  Cell       Date:  2004-01-23       Impact factor: 41.582

3.  Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737.

Authors:  Victoria Del Gaizo Moore; Jennifer R Brown; Michael Certo; Tara M Love; Carl D Novina; Anthony Letai
Journal:  J Clin Invest       Date:  2007-01       Impact factor: 14.808

4.  Bcl-2 functions in an antioxidant pathway to prevent apoptosis.

Authors:  D M Hockenbery; Z N Oltvai; X M Yin; C L Milliman; S J Korsmeyer
Journal:  Cell       Date:  1993-10-22       Impact factor: 41.582

Review 5.  Mitochondria and apoptosis.

Authors:  D R Green; J C Reed
Journal:  Science       Date:  1998-08-28       Impact factor: 47.728

Review 6.  BCL-2 family: regulators of cell death.

Authors:  D T Chao; S J Korsmeyer
Journal:  Annu Rev Immunol       Date:  1998       Impact factor: 28.527

7.  Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked.

Authors:  J Yang; X Liu; K Bhalla; C N Kim; A M Ibrado; J Cai; T I Peng; D P Jones; X Wang
Journal:  Science       Date:  1997-02-21       Impact factor: 47.728

8.  In leukaemic CD5+ B cells the expression of BCL-2 gene family is shifted toward protection from apoptosis.

Authors:  D Gottardi; A Alfarano; A M De Leo; A Stacchini; M Aragno; A Rigo; D Veneri; R Zanotti; G Pizzolo; F Caligaris-Cappio
Journal:  Br J Haematol       Date:  1996-09       Impact factor: 6.998

9.  The bcl-2 candidate proto-oncogene product is a 24-kilodalton integral-membrane protein highly expressed in lymphoid cell lines and lymphomas carrying the t(14;18) translocation.

Authors:  Z Chen-Levy; J Nourse; M L Cleary
Journal:  Mol Cell Biol       Date:  1989-02       Impact factor: 4.272

Review 10.  The mammalian unfolded protein response.

Authors:  Martin Schröder; Randal J Kaufman
Journal:  Annu Rev Biochem       Date:  2005       Impact factor: 23.643

View more
  6 in total

1.  17-DMAG targets the nuclear factor-kappaB family of proteins to induce apoptosis in chronic lymphocytic leukemia: clinical implications of HSP90 inhibition.

Authors:  Erin Hertlein; Amy J Wagner; Jeffrey Jones; Thomas S Lin; Kami J Maddocks; William H Towns; Virginia M Goettl; Xiaoli Zhang; David Jarjoura; Chelsey A Raymond; Derek A West; Carlo M Croce; John C Byrd; Amy J Johnson
Journal:  Blood       Date:  2010-03-29       Impact factor: 22.113

2.  Excessive antigen reactivity may underlie the clinical aggressiveness of chronic lymphocytic leukemia stereotyped subset #8.

Authors:  Maria Gounari; Stavroula Ntoufa; Benedetta Apollonio; Nikos Papakonstantinou; Maurilio Ponzoni; Charles C Chu; Davide Rossi; Gianluca Gaidano; Nicholas Chiorazzi; Kostas Stamatopoulos; Paolo Ghia
Journal:  Blood       Date:  2015-04-21       Impact factor: 22.113

3.  Bcl-2 level as a biomarker for 13q14 deletion in CLL.

Authors:  Heba A Degheidy; Shahinaz M Gadalla; Mohammed Z H Farooqui; Fatima Abbasi; Diane C Arthur; Steven R Bauer; Wyndham H Wilson; Adrian Wiestner; M A Stetler-Stevenson; Gerald E Marti
Journal:  Cytometry B Clin Cytom       Date:  2013-05-14       Impact factor: 3.058

Review 4.  Role of insulin-like growth factor-binding proteins in the pathophysiology and tumorigenesis of gastroesophageal cancers.

Authors:  Manoj K Kashyap
Journal:  Tumour Biol       Date:  2015-09-14

5.  Extracellular administration of BCL2 protein reduces apoptosis and improves survival in a murine model of sepsis.

Authors:  Akiko Iwata; R Angelo de Claro; Vicki L Morgan-Stevenson; Joan C Tupper; Barbara R Schwartz; Li Liu; Xiaodong Zhu; Katherine C Jordan; Robert K Winn; John M Harlan
Journal:  PLoS One       Date:  2011-02-24       Impact factor: 3.240

6.  Role of CTLA4 in the proliferation and survival of chronic lymphocytic leukemia.

Authors:  Amit K Mittal; Nagendra K Chaturvedi; Rae A Rohlfsen; Payal Gupta; Avadhut D Joshi; Ganapati V Hegde; R Gregory Bociek; Shantaram S Joshi
Journal:  PLoS One       Date:  2013-08-01       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.